




RealRate

PHARMACEUTICAL 2018

Corbus Pharmaceuticals Holdings Inc. Rank 90 of 342





RealRate

PHARMACEUTICAL 2018

Corbus Pharmaceuticals Holdings Inc. Rank 90 of 342



The relative strengths and weaknesses of Corbus Pharmaceuticals Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corbus Pharmaceuticals Holdings Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 109% points. The greatest weakness of Corbus Pharmaceuticals Holdings Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 176%, being 130% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	65,505
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,205
Liabilities, Non-Current	0.38
Other Assets	41
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	990
Other Net Income	141
Other Revenues	2,440
Property and Equipment	1,433
Research and Development	26,039
Selling, General and Administrative Expense	8,964

Output Variable	Value in 1000 USD
Assets	66,978
Liabilities	9,195
Expenses	35,003
Revenues	2,440
Stockholders Equity	57,784
Net Income	-32,422
Comprehensive Net Income	-32,422
Economic Capital Ratio	176%